|
What is Zyprexa?
Zyprexa, which has the generic name olanzapine, was introduced in 1996 and is currently marketed by Eli Lilly and Company. Zyprexa falls into the category of pharmaceuticals known as second-generation or atypical antipsychotics, which were introduced as a new class of medications for the treatment of schizophrenia. The drugs classified as atypical antipsychotics are prescribed for the treatment of symptoms associated with schizophrenia and bipolar I disorder. Schizophrenia, a mental illness that can distort the way you perceive the world around you, may include symptoms such as delusions, hearing voices or seeing things. People with bipolar I disorder, a mood disorder also known as manic-depressive disorder, may suffer from manic episodes. In addition to Zyprexa, other medications that fall into the atypical antipsychotic category include Abilify, Risperdal, and Seroquel.
Zyprexa Side Effects
Similarly to other atypical antipsychotics, Zyprexa may be linked to harmful side effects such as neuroleptic malignant syndrome (also referred to as NMS), tardive dyskinesia (also referred to as TD), stroke, diabetes, weight gain, and high blood sugar. A clinical study has reported that there exists an increased risk of stroke and ministroke in elderly patients with dementia-related psychosis who are treated with atypical antipsychotics, which has lead to a black box warning for Zyprexa and other atypical antipsychotics.
Atypical antipsychotics in general have been linked to increasing the risk of obesity, weight gain, high cholesterol, as well as diabetes and hyperglycemia in schizophrenia patients who take these drugs. The risk of diabetes and hyperglycemia is increased further in those patients that have additional risk factors such as preexisting obesity or family history of diabetes. The FDA has requested that manufacturers of atypical antipsychotics, including Eli Lilly, the producer of Zyprexa, to include a warning about the risks of diabetes on its labeling. Obesity, high cholesterol and diabetes are all factors linked to increasing the risk of developing heart disease, which can lead to death. A panel of four health organizations, the American Diabetes Association, American Association of Clinical Endocrinologists, the North American Association for the Study of Obesity, and the American Diabetes Association, indicated in a consensus statement that Zyprexa is linked to the highest risk of diabetes and weight gain among the atypical antipsychotics.
Zyprexa Settlement and Seeger Weiss LLP
On June 7, 2005, Eli Lilly and Christopher Seeger of Seeger Weiss LLP, on behalf of the Plaintiff's Steering Committee in the federal Zyprexa MDL, announced a $700 million settlement. This settlement consists of approximately 8,000 cases against Eli Lilly, dealing with allegations that the atypical anti-psychotic drug Zyprexa caused patients to develop diabetes and diabetes-related injuries.
Link To Lawyer Seek's Zyprexa Content:
<a href='http://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Zyprexa-P34/'>Zyprexa: Lawyer Seek</a> |
|
Sorry; we are currently not taking clients for this case. |
|
| | |
